Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James DeMicco

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Drug Safety|June 1, 2007
'Extreme duplication' in the US FDA Adverse Events Reporting System databaseManfred Hauben, Lester Reich, James DeMicco, et al.
Substance Abuse|May 18, 2019
Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and PreventionStefan G Kertesz, Sally L Satel, James DeMicco, et al.
Substance Abuse|July 31, 2019
Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and PreventionStefan G Kertesz, Sally L Satel, James DeMicco, et al.
Journal of Addiction Medicine|August 1, 2022
Three-year Retention Rates With Office-based Treatment of Buprenorphine for Opioid Use Disorder in a Private Family Medicine PracticeKevin Cope, James DeMicco, Justina Salib, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Drug Safety|June 1, 2007
'Extreme duplication' in the US FDA Adverse Events Reporting System databaseManfred Hauben, Lester Reich, James DeMicco, et al.
Substance Abuse|May 18, 2019
Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and PreventionStefan G Kertesz, Sally L Satel, James DeMicco, et al.
Substance Abuse|July 31, 2019
Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and PreventionStefan G Kertesz, Sally L Satel, James DeMicco, et al.
Journal of Addiction Medicine|August 1, 2022
Three-year Retention Rates With Office-based Treatment of Buprenorphine for Opioid Use Disorder in a Private Family Medicine PracticeKevin Cope, James DeMicco, Justina Salib, et al.
Pageof 1